Abstract
The hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used hypolipidemic agents which decrease cardiovascular morbidity and mortality in both primary and secondary prevention. Lovastatin, simvastatin, atorvastatin, fluvastatin, pravastatin and rosuvastatin are globally available. In general, statins are well tolerated, and serious adverse effects are rare. The most important adverse effect of statins is myopathy [1–3]. Clinically relevant myopathy is often defined as a proximal or generalised pain and/or weakness in skeletal muscles, and a creatine phosphokinase (CK) value higher than ten times the upper limit of the normal range. Statin-associated myopathy may also occur with normal CK levels [4]. Statin myopathy can progress to necrosis of muscle cells (rhabdomyolysis) which may lead to myoglobinuria and acute renal failure [1–3]. CYP3A4 catalyses the biotransformation of lovastatin, simvastatin and atorvastatin [5]. Erythromycin, clarithromycin, itraconazole and ketoconazole are examples of widely used drugs that inhibit CYP3A4. The concomitant use of these drugs with lovastatin, simvastatin or atorvastatin leads to increased bioavailability and reduced elimination of the statin, thereby greatly increasing the potential for myotoxicity [2, 5, 6]. One case of rhabdomyolysis after concomitant use of fluconazole and simvastatin has been reported [7], but, to our knowledge, there are no reported cases of rhabdomyolysis associated with concomitant intake of fluconazole and atorvastatin. We describe a fatal case of rhabdomyolysis in a 76-year-old male after use of this drug combination.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.